The Partners in Bleeding Disorders Education Program has relaunched an ethics-related educational activity for healthcare providers at hemophilia treatment centers (HTCs).
AbbVie recently announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for glecaprevir/pibrentasvir (G/P).
As of February 1, 2017, the new company, known as Bioverativ, became an independent global biotechnology company focused on hemophilia and other rare blood disorders.
NHF offers guidance for those who may be affected by current travel restrictions.
This Breakthrough designated therapy is put on a fast-track approval program from the FDA and could dramatically reduce the frequency of bleeding episodes in people with hemophilia B.
NHF will showcase important bleeding disorder research currently being conducted by physicians, researchers and other healthcare professionals at the NHF 69th Annual Meeting in Chicago, IL
This update describes wellness not just in terms of the presence or absence of disease or illness but as a multidimensional collection of behaviors that contribute to the quality of life in a person with a bleeding disorder.
With the new Congress and Trump Administration in place, it’s a good time to contact Congress and tell them how the Affordable Care Act has affected your life.
The winning artist will have $2,500 awarded toward their Walk team in 2017.
Healthcare professionals, register now for February CDC webinar on new NHF-McMaster hemophilia care guidelines.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car